$オンコリティクス バイオテック(ONCY.US)$A Type C meeting with the Food and Drug Administration in the coming few weeks will establish registrational pathway for Oncolytic Biotech's pelareorep in HR+/HER2- metastatic breast cancer, notes RBC. Following discussions with the clinical advisors, collaborators, and potential partners over the last year, Oncolytics aims to conduct an "efficiently sized," cost-effective, randomized, controlled study that with positive data could lead directly to a...
$オンコリティクス バイオテック(ONCY.US)$ NEWS Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expecte...
Trytosaveabitスレ主MonkeyGee:
Yeah if you’re talking about that drop starting back in July? It was the start of a lot being pissed at the offering at a discount! Hehehe! But you see, im not afeared! Hehehe. I look at it as a good place to start a swing! Because I believe in 6+ weeks or so! The FDA will approve the go forward and I will grab a quick 50%+! Hehehe!
$オンコリティクス バイオテック(ONCY.US)$Ifn you drop to a 1.00? Ima start scaling in for a swing, in preparation for a answer from the FDA for your next phase trial design! NFA Just thinking outloud! Hehehe
$オンコリティクス バイオテック(ONCY.US)$Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDA Benzinga· 3 mins ago This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a tr...
$オンコリティクス バイオテック(ONCY.US)$ NEWS Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
Patricia S. Andrews joining Oncolytics Biotech Inc.'s Board of Directors is viewed positively. Her vast experience in oncology and business development is anticipated to offer valuable insights and strategic direction as the company gears up for crucial studies with pelareorep in breast and pancreatic cancers.
$オンコリティクス バイオテック(ONCY.US)$Oncolytics Biotech Brief: Cash Position Stands at $40.0 Million With a Projected Cash Runway Through Critical Milestones, Including BRACELET-1 Survival Data! Important meaning they think news of meeting milestones coming soon? At least soon enough that they dont need the cash right now? WATCHING CLOSELY
$オンコリティクス バイオテック(ONCY.US)$Oncolytics Biotech Brief: Adds Presented "Positive" Updated Pancreatic Cancer Data From GOBLET Phase 1/2 Study At ESMO MT Newswires· 2 mins ago
オンコリティクス バイオテックに関するコメント
Following discussions with the clinical advisors, collaborators, and potential partners over the last year, Oncolytics aims to conduct an "efficiently sized," cost-effective, randomized, controlled study that with positive data could lead directly to a...
NEWS
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expecte...
Benzinga· 3 mins ago
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a tr...
NEWS
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
MT Newswires· 2 mins ago
まだコメントはありません